tirzepatide surpass trials Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial New Dual Incretin Agonist for

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 17 trials

They can help with weight loss and lower the risk of serious health conditions

FDA-Approved Medications (Wegovy, Ozempic, Mounjaro, Zepbound) are manufactured by their original drug makers and approved through the full FDA review process

By combining genetic insights with compounded therapy, PlexusDx patients gain advantages that insurance-only pathways cannot match: personalized medication selection, transparent flat-rate pricing, and rapid access without authorization bottlenecks